- Home
- CYRX vs EIKN Comparison
CYRX vs EIKN Comparison
Compare CYRX & EIKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$15.37
N/A
Current Price
$9.55
Company Overview
Basic Information| Metric | CYRX | EIKN |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 774.7M | 731.6M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | CYRX | EIKN |
|---|---|---|
| Price | $15.37 | $9.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $13.31 | ★ $25.60 |
| AVG Volume (30 Days) | ★ 655.5K | 307.9K |
| Earning Date | 05-04-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $176,177,000.00 | N/A |
| Revenue This Year | $11.06 | N/A |
| Revenue Next Year | $8.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.69 | $7.90 |
| 52 Week High | $16.89 | $16.50 |
Technical Indicators
Market Signals| Indicator | CYRX | EIKN |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 40.67 |
| Support Level | $14.54 | $8.16 |
| Resistance Level | $16.76 | $13.52 |
| Average True Range (ATR) | 0.81 | 0.75 |
| MACD | -0.19 | -0.14 |
| Stochastic Oscillator | 13.66 | 11.20 |
Price Performance
Historical Comparison CYRX
EIKN
About CYRX CryoPort Inc.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.